Inflammation-resolution Therapy in MINST of Periodontal Intrabony Defect: a Pilot Randomised Controlled Trial

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-11-01

Study Completion Date

2027-05-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this study is to assess whether and how a mouthwash containing an ingredient that reduces inflammation in combination with a recently developed treatment is more effective at improving advanced gum disease. Advanced gum disease, also called periodontitis, is an inflammation of the gums which results in decrease in bone levels supporting teeth and can result in tooth loss. Minimally invasive non-surgical treatment (MINST) is a type of deep cleaning of teeth which involves removal of plaque beneath the gum margin and reduces inflammation. In this trial we will assess the additional benefits of combining deep cleaning (MINST) with the use of a mouthwash known to have a beneficial effect on tissue healing by helping the body to 'switch off' inflammation in periodontitis. Participants may be part of a control group, where you they be treated by MINST and provided with a placebo mouthwash The placebo mouthwash does not contain the active ingredient which reduces inflammation. Neither the participants nor the investigators can decide or be aware of which mouthwash the participants be given, as this will be determined randomly and the two mouthwash packages look the same.

The duration of the study will be over six months and will consist of a total of seven appointments. The aim of this study is to assess whether we can achieve better outcomes using this mouthwash and the healing of thegums will be assessed clinically. In addition, other parameters such as saliva samples, blood samples and plaque samples will be collected throughout the study, which allows us to examine the healing process in more detail and will help us understand how exactly the combination of MINST and the mouthwash improve healing.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Comparison of Adjunctive Chemomechanical Therapy With Standard Care in Patients With Periodontitis

NCT05757921

Periodontitis

COMPLETED NA

A Clinical Study Investigating the Efficacy of a Stannous Fluoride Dentifrice in Improving Gingival Health After Twice Daily Use for 3 Weeks

NCT04050722

Gingivitis

COMPLETED PHASE4

Efficacy of Iocide Oral Rinse Against Gingival Inflammation

NCT01782170

Gingivitis Investigation of Biological Markers of Inflammation

UNKNOWN PHASE2

A Clinical Study Investigating the Effects of a Dentifrice Containing 0.454% Stannous Fluoride on Gingivitis Treatment and Plaque Reduction When Used Twice Daily for 12 Weeks

NCT06143670

Gingivitis

COMPLETED NA

Potential of Stannous Fluoride Toothpaste to Reduce Gum Disease

NCT02750943

Gingivitis

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a pilot randomised controlled trial comparing patients being treated with MINST non-surgical therapy with an adjunctive test or placebo mouthwash. This will be a single centre trial in the Department of Periodontology at Guy's Dental Hospital. Patients will be recruited and treated at this centre as per the inclusion criteria. The primary outcome is PPD reduction at 6 months in test vs control group, and the secondary outcomes are CAL reduction at 6 months, changes in inflammatory/tissue degradation/repair biomarkers in saliva and GCF between baseline and 6 months post-treatment.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Periodontal Diseases Periodontitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

MINST + test adjunctive anti-inflammatory mouthwash

Patients being treated with MINST non-surgical therapy with an adjunctive test mouthwash (IsoDent Paro Strong)

Group Type EXPERIMENTAL

IsoDent Paro Strong (Isodent Ltd. Valtakatu 4 D, 96100 Rovaniemi, Finland) mouthwash

Intervention Type DEVICE

adjunctive anti-inflammatory mouthwash

MINST + placebo mouthwash

Patients being treated with MINST non-surgical therapy with an adjunctive placebo mouthwash

Group Type PLACEBO_COMPARATOR

Placebo mouthwash

Intervention Type DEVICE

Contains all the inactive ingredients as the test mouthwash without the LXA4

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

IsoDent Paro Strong (Isodent Ltd. Valtakatu 4 D, 96100 Rovaniemi, Finland) mouthwash

adjunctive anti-inflammatory mouthwash

Intervention Type DEVICE

Placebo mouthwash

Contains all the inactive ingredients as the test mouthwash without the LXA4

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Age 18 to 70
2. Diagnosis of periodontitis stage III-IV
3. Presence of at least 1 deep intrabony defect (both PPD and radiographic defects \>6mm)
4. Full-mouth dichotomous plaque score\>30%
5. Willing to voluntarily sign the informed consent.

Exclusion Criteria

1. Previous periodontal treatment to the study site within 6 months
2. Use of systemic antibiotics within 3 months
3. Weekly regular use of non-steroidal anti-inflammatory drugs
4. Contributing medical history according to the examining clinician (e.g. diabetes mellitus)
5. Smoking history (current or within 5 years)
6. Allergic to any ingredient present in the products used in study.
7. Presence of systemic diseases, which affects bone and/or connective tissue metabolism
8. Concurrent participation in other clinical studies.
9. Pregnant or breastfeeding.

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No